OBJECTIVES: To assess the effectiveness of shortened regimens of vancomycin or fidaxomicin in the treatment of Clostridioides difficile infection (CDI). METHODS: Adult patients with CDI hospitalized from January 2022 to May 2023 were included in this observational study. In patients with CDI treated with vancomycin or fidaxomicin, antibiotic treatment was discontinued after either 5 or 7 days of vancomycin or 5 days of fidaxomicin if there was a clinical response and improvement in laboratory parameters. The control cohort was treated with the standard 10 day regimen of either vancomycin or fidaxomicin. The follow-up was 60 days. Causative C. difficile strains were characterized by ribotyping and toxin gene detection when available. RESULTS: Twenty-five patients (median age 76 years) received shortened treatment with vancomycin (n = 21), or fidaxomicin (n = 4). Five cases fulfilled the criteria for severe CDI. Twenty-three patients completed follow-up; two died from causes other than CDI, and two developed recurrent CDI (8.0%). Ribotypes (RTs) 001 and 014 were the most prevalent with 20% each. In two C. difficile isolates, binary toxin genes were detected (RTs 078 and 023). In the control group of 22 patients recurrent CDI developed in 5 patients (22.7%). No statistically significant differences were found between the groups. CONCLUSIONS: Shortened treatment regimens for CDI with vancomycin and fidaxomicin were shown to be effective in our cohort of patients compared with 10 days of treatment. The recurrence rate was lower in the study group. A larger, prospective, double-blind, randomized, multicentre study is needed to support our findings.

Department of Clinical Microbiology University Hospital Bulovka Prague Czech Republic

Department of Infectious Diseases 3rd Faculty of Medicine Charles University and University Hospital Bulovka Budínova 67 2 180 81 Praha 8 Prague Czech Republic

Department of Medical Microbiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Nicolaou K, Rigol S. A brief history of antibiotics and select advances in their synthesis. J Antibiot 2018; 71: 153–84. 10.1038/ja.2017.62 PubMed DOI

Zanella Terrier MC, Simonet ML, Bichard Pet al. . Recurrent Clostridium difficile infections: the importance of the intestinal microbiota. World J Gastroenterol 2014; 20: 7416–23. 10.3748/wjg.v20.i23.7416 PubMed DOI PMC

Di Bella S, Ascenzi P, Siarakas Set al. . Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins (Basel) 2016; 8: 134. 10.3390/toxins8050134 PubMed DOI PMC

Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI)—a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis 2021; 21: 456. 10.1186/s12879-021-06147-y PubMed DOI PMC

van Prehn J, Reigadas E, Vogelzang HEet al. . European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infections in adults. Clin Microbiol Infect 2021; 2: S1–21. 10.1016/j.cmi.2021.09.038 PubMed DOI

Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46: S32–42. 10.1086/521860 PubMed DOI

Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc 2011; 86: 1113–23. 10.4065/mcp.2011.0358 PubMed DOI PMC

Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: a systematic review of randomized controlled trials. Pharmacotherapy 2018; 38: 674–87. 10.1002/phar.2118 PubMed DOI

Michael M, Hodson EM, Craig JCet al. . Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child 2002; 87: 118–23. 10.1136/adc.87.2.118 PubMed DOI PMC

Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better. Ann Intern Med 2019; 171: 210–1. 10.7326/M19-1509 PubMed DOI PMC

McDonald LC, Gerding DN, Johnson Set al. . Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: e1–48. 10.1093/cid/cix1085 PubMed DOI PMC

Grayson ML, Kucers A, Crowe Set al. . Kucers’ the Use of Antibiotics, 6th ed. Hodder Arnold, 2010.

Beneš J, Stebel R, Musil Vet al. . Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile. Klin Mikrobiol Infekc Lek 2022; 28: 77–94. PubMed

Fawley WN, Knetsch CW, MacCannell DRet al. . Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. PLoS One 2015; 10: e0118150.10.1371/journal.pone.0118150 PubMed DOI PMC

Kim AH, Lee Y, Kim Eet al. . Assessment of oral vancomycin-induced alterations in gut bacterial microbiota and metabolome of healthy men. Front Cell Infect Microbiol 2021; 11: 629438. 10.3389/fcimb.2021.629438 PubMed DOI PMC

Krutova M, Wilcox M, Kuijper E. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? Int J Infect Dis 2022; 124: 118–23. 10.1016/j.ijid.2022.09.013 PubMed DOI

Freeman J, Vernon J, Morris Ket al. . Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 2015; 21: 248.e9–e16. 10.1016/j.cmi.2014.09.017 PubMed DOI

Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic-associated colitis due to Clostridium difficile. Gut 1986; 27: 1169–72. 10.1136/gut.27.10.1169 PubMed DOI PMC

Eyre DW, Walker AS, Wyllie Det al. . Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55: S77–87. 10.1093/cid/cis356 PubMed DOI PMC

Wingen-Heimann SM, Davies K, Viprey VFet al. . Clostridioides difficile infection (CDI): a pan-European multi-center cost and resource utilization study, results from the combatting bacterial resistance in Europe CDI (COMBACTE-CDI). Clin Microbiol Infect 2023; 29: 651.e1–e8. 10.1016/j.cmi.2022.12.019 PubMed DOI

Krutova M, Nyc O, Matejkova Jet al. . Molecular characterisation of Czech Clostridium difficile isolates collected in 2013–2015. Int J Med Microbiol 2016; 306: 479–85. 10.1016/j.ijmm.2016.07.003 PubMed DOI

Kracík M, Dolinová I, Žemličková H. Ribotyping of Clostridioides difficile in the Liberec regional hospital: a tertiary health care facility. Folia Microbiol 2023; 68: 315–20. 10.1007/s12223-022-01021-z. PubMed DOI PMC

Krutova M, Matejkova J, Drevinek Pet al. . Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur J Clin Microbiol Infect Dis 2017; 36: 2251–8. 10.1007/s10096-017-3055-z PubMed DOI